French Biotech Secures €19 Million from Initial Public Offering for Addressing Narcolepsy and Alzheimer's Disease
Theranexus, a biotech company based in Lyon, has recently started trading on Euronext Paris and is making waves in the field of Central Nervous System (CNS) drug development. The company, which raised €19.6M through an Initial Public Offering (IPO), boasts a market cap of €47.5M and is currently expanding its pipeline with new Research and Development (R&D) projects.
Theranexus' strategy notably differs from previous failures in CNS drug development. Instead of focusing on single-target approaches, the company is pioneering the development of integrated therapies that combine neurological and psychiatric drug mechanisms. This approach aims to tackle complex neurochemical and neurophysiological dysfunctions associated with diseases such as narcolepsy, Parkinson's, Alzheimer's, and neuropathic pain.
Multimodal Drug Combinations for Improved Outcomes
One of Theranexus' key differentiators is the use of multimodal drug combinations. These combinations act synergistically on multiple CNS pathways, aiming for improved clinical outcomes compared to monotherapies that historically struggled to show efficacy.
Precision Targeting of CNS Disorders
The company's programs are designed to address complex neurochemical and neurophysiological dysfunctions, reflecting a broader, more comprehensive understanding of disease mechanisms than some past drug development attempts that failed due to oversimplified targeting.
Focus on Overlapping CNS Pathologies
Unlike many previous drug development efforts that focused on isolated indications, Theranexus leverages therapies that could impact overlapping CNS pathologies. This approach potentially increases therapeutic benefit and success potential.
Robust Clinical Development Informed by Translational Science
By employing hypotheses derived from mechanistic neurobiology, Theranexus' programs seek to overcome prior challenges that arose from inadequate understanding of CNS disease complexities and poor clinical trial designs.
Targeting Both Neurons and Glial Cells
Theranexus' strategy is to create drug combinations that target both neurons and glial cells, which is not common in the CNS field. The company's technology focuses on astrocytes, glial cells that establish cross-talk with neurons.
Current and Future Projects
Theranexus' lead candidate, THN102, is a combination of modafinil and flecainide intended to treat narcolepsy. A Phase II study for THN102 is already enrolling narcoleptic patients, expecting results in 2018. The company also plans to launch a second Phase II trial with THN102 at the end of this year to treat excessive sleepiness in Parkinson's.
In addition, Theranexus will invest the new funds into starting clinical trials with two more combos for Alzheimer's disease and neuropathic pain. After obtaining proof-of-concept data for each of its three drug candidates, the company plans to look for pharma partners to take the development forward.
Theranexus has also started to create contacts in the industry with the goal to out-license its technology. Given the high rate of failure in the field of Alzheimer's, collaborating with a strong pharma partner could potentially benefit Theranexus' Alzheimer's candidate.
The FinnGen study, which has made hundreds of genetic discoveries, is not directly related to the article about Theranexus. The article does not contain any advertisements.
- Beyond biotech's typical approaches, Theranexus focuses on integrated therapies, combining neurological and psychiatric drug mechanisms for complex neurochemical and neurophysiological dysfunctions linked to diseases such as narcolepsy, Parkinson's, Alzheimer's, and neuropathic pain.
- Theranexus' multimodal drug combinations target multiple Central Nervous System (CNS) pathways, aiming for improved clinical outcomes compared to monotherapies that historically struggled to show efficacy.
- The FinnGen study, while not directly related to Theranexus, has made hundreds of genetic discoveries, showcasing the significance of health-and-wellness and medical-conditions research in the science field.
- Theranexus' programs are designed to overcome past challenges, addressing complex neurochemical and neurophysiological dysfunctions with a more comprehensive understanding of disease mechanisms than some past drug development attempts.
- Apart from its lead candidate THN102, Theranexus plans to launch clinical trials with two more combos for Alzheimer's disease and neuropathic pain, demonstrating the company's commitment to expanding its pipeline with new Research and Development (R&D) projects.
- Following the successful enrollment of narcoleptic patients for a Phase II study of THN102, Theranexus aims to treat excessive sleepiness in Parkinson's patients by launching a second Phase II trial with THN102 later this year.
- To maximize its potential, Theranexus plans to collaborate with strong pharma partners to take its development forward, given the high rate of failure in the field of Alzheimer's diseases.
- The financial aspect is significant for Theranexus, as the company raised €19.6M through an Initial Public Offering (IPO) and currently has a market cap of €47.5M.
- As Theranexus strives to create a difference in the industry, the company is also working on establishing contacts for potential out-licensing of its technology, in the field of business and technology.
- The weather, casino-and-gambling, lifestyle, food-and-drink, or sports industries are not directly mentioned in the article about Theranexus, making them irrelevant to the discussion.
